Clinical Trial Update: Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers. [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study evaluating a single dose of darifenacin 7.5 mg tablets in fed healthy volunteers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Darifenacin (darifenacin)

Snippet

Sponsor: Center for Clinical Pharmacology Research Bdbeq S.A. | Conditions: Bioequivalency | Phase 1 | Status: UNKNOWN